RE:RE:JV vs Buyout
ScienceFirst wrote: No.
Many biotechs have deals with different big pharmas before being taken over by a big pharma.
It can only be positive and even start a bidding war as more big pharmas can realize how good is the scientific platform.
Once Pharma & specialists (oncologists/surgeons) see success using our unique drug, it should have a snowball effect on other suitable indications imo.
Photofrin PDT had set a relatively low standard in view of its lower selectivity, dark toxicity & other adverse side effects (i.e. weeks/months of photosensitivity). Because of the above, both surgical & oncological specialty organizations had put in place more strict criteria regarding when to use PDT. Well, it's been nearly 20 yrs since Photofrin was approved in the US, & sadly, the guidelines for its use haven't changed much (or at all) in that time & it is still the go-to photosensitizer.
It's about time that Pharma & clinicians wake up to a new order of PDT as both a stand-alone & adjuvant option. Looking forward to the floodgates opening once we get to Nasdaq with a BTD/AA in hand. Good luck...